ABVX
- Abivax SA
()
Overview
Company Summary
Abivax SA is a biotechnology company focused on developing innovative treatments for infectious diseases and inflammatory disorders. The company combines cutting-edge science, clinical expertise, and a deep understanding of the immune system to create novel therapeutic solutions.
Abivax is primarily engaged in researching and developing small molecule drugs known as antiviral compounds, which target viral replication enzymes and modulate the immune system response to combat infectious diseases. The company's lead product candidate, ABX464, is being investigated for its potential to treat and achieve a functional cure for HIV/AIDS.
The company also has a diverse pipeline of other candidate drugs, including ABX196 for the treatment of chronic hepatitis B and ABX544 for the prevention and treatment of various viral infections. Additionally, Abivax is developing therapeutic vaccines that aim to stimulate the immune system to fight infectious diseases.
Abivax focuses on conducting rigorous preclinical and clinical studies to assess the safety and efficacy of its product candidates. The company collaborates with leading academic institutions and partners with pharmaceutical companies to advance its drug development programs.
In summary, Abivax SA is a biotech company dedicated to developing innovative therapies targeting infectious diseases and inflammatory disorders, with a particular focus on antiviral compounds and immunomodulation.